Skip to content

Evofem Biosciences, Inc.

About Us
Our Product
- phexxi^®
Pipeline
Investors
Contact

Press Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Year Keywords

Advanced Search

Search

Search Headlines Only

From

To

Asset Types

Photos Video Audio Documents Events Standard

Nov 14, 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
Nov 6, 2024

Evofem Secures Investor Support for Proposed Merger through Voting Agreements
Oct 28, 2024

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
Sep 20, 2024

Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
Sep 9, 2024

Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
Aug 20, 2024

Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution
Aug 14, 2024

Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
Jul 25, 2024

Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Jul 23, 2024

Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Jul 15, 2024

Lupin Divests U.S. Commercial Women's Health Specialty Business - SOLOSEC - to Evofem Biosciences
Jun 27, 2024

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
- Photos 1
Jun 11, 2024

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
May 15, 2024

Evofem Biosciences Announces Financial Results for the First Quarter of 2024
Apr 18, 2024

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
Mar 27, 2024

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
Mar 20, 2024

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
Mar 7, 2024

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
Feb 1, 2024

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Jan 8, 2024

Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
Dec 12, 2023

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
Nov 14, 2023

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
Oct 24, 2023

Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
Oct 13, 2023

Evofem to Participate in the Virtual Investor Ask the CEO Conference
Sep 27, 2023

Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
Sep 11, 2023

Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
Aug 22, 2023

Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
Aug 14, 2023

Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
Jul 6, 2023

Evofem to Participate in the Virtual Investor Summer Spotlight Series
Jun 16, 2023

Evofem Biosciences Announces Financial Results for the First Quarter of 2023
Jun 1, 2023

Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
May 17, 2023

Evofem Biosciences Announces 1-for-125 Reverse Stock Split
Apr 28, 2023

Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
Apr 14, 2023

Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
Apr 12, 2023

Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
Mar 21, 2023

Evofem Biosciences Announces Cost Reduction Measures
Mar 9, 2023

Evofem Biosciences Appoints Interim Chief Financial Officer
Feb 28, 2023

Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering
Feb 27, 2023

Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
Feb 23, 2023

Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value
Jan 12, 2023

Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)
- Photos 1
Jan 10, 2023

Costco Adds Phexxi® to Member Prescription Program
Jan 9, 2023

Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women
Dec 29, 2022

OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
Oct 11, 2022

Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women
Oct 6, 2022

Evofem Biosciences Announces Approval of Phexxi in Nigeria
Oct 3, 2022

Evofem Biosciences Announces Uplisting to OTCQB
Sep 23, 2022

Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter
Sep 19, 2022

Inventor of the Year Awarded to Developer of Phexxi®
Sep 16, 2022

Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide
Sep 16, 2022

Evofem Announces Successful Debt Restructuring

Show 5 10 25 50 100 per page

«
1
2
3
4
5
»

7770 Regents Rd. Suite 113-618
San Diego, California 92122
1.858.550.1900

Phexxi^® and the Phexxi^® logo are registered trademarks of Evofem Biosciences, Inc.

Quick Links

About Us
Phexxi ^®
Pipeline

Contact

Investor
Media
General
Careers

© 2024 Evofem Biosciences, Inc.

Privacy Policy
Legal
Compliance